| Description | DCLK2 Human Pre-designed siRNA Set A contains three designed siRNAs for DCLK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components DCLK2 siRNA-1: 5 nmol (HPLC) DCLK2 siRNA-2: 5 nmol (HPLC) DCLK2 siRNA-3: 5 nmol (HPLC) siRNA Negative Control:DCLK2 Human Pre-designed siRNA Set A contains three designed siRNAs for DCLK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components DCLK2 siRNA-1: 5 nmol (HPLC) DCLK2 siRNA-2: 5 nmol (HPLC) DCLK2 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)... Read More | Purity>95% SDS-PAGEFunctionLipid transport protein in adipocytes. Binds both long chain fatty acids and retinoic acid. Delivers long-chain fatty acids and retinoic acid to their cognate receptors in the nucleus | purity>97% by SDS-PAGE and HPLC analysesFunctionFunctionElicits growth inhibition on melanoma cells in vitro as well as some other neuroectodermal tumors, including gliomas.Post-translationalMay possess two intramolecular disulfide bonds | Purity> 95 % by SDS-PAGE and HPLC analyses.FunctionOsteoprotegerin (OPG), also named osteoclastogenesis inhibitory factor (OCIF), and tumor necrosis factor receptor superfamily member 11B (TNFRSF11B), is a TNFRSF11B-encoded protein in humans. Acts as decoy receptor for RANKL and thereby Purity> 95 % by SDS-PAGE and HPLC analyses.FunctionOsteoprotegerin (OPG), also named osteoclastogenesis inhibitory factor (OCIF), and tumor necrosis factor receptor superfamily member 11B (TNFRSF11B), is a TNFRSF11B-encoded protein in humans. Acts as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis.OPG has been applied to decrease bone resorption in women with postmenopausal osteoporosis and in patients with lytic bone metastases... Read More | Inquire |